Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes

The 2018 US cholesterol management guidelines recommend additional lipid-lowering therapies for secondary prevention in patients with low-density lipoprotein cholesterol ≥70 mg/dL or non−high-density lipoprotein cholesterol ≥100 mg/dL despite maximum tolerated statin therapy. Such patients are consi...

Descripción completa

Detalles Bibliográficos
Autores principales: Roe, Matthew T., Li, Qian H., Bhatt, Deepak L., Bittner, Vera A., Diaz, Rafael, Goodman, Shaun G., Harrington, Robert A., Jukema, J. Wouter, Lopez-Jaramillo, Patricio, Lopes, Renato D., Louie, Michael J., Moriarty, Patrick M., Szarek, Michael, Vogel, Robert, White, Harvey D., Zeiher, Andreas M., Baccara-Dinet, Marie T., Steg, Ph. Gabriel, Schwartz, Gregory G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2019
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6830944/
https://www.ncbi.nlm.nih.gov/pubmed/31475572
http://dx.doi.org/10.1161/CIRCULATIONAHA.119.042551

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6830944/
https://www.ncbi.nlm.nih.gov/pubmed/31475572
http://dx.doi.org/10.1161/CIRCULATIONAHA.119.042551

Ejemplares similares